Registration is now open for the 2024 Veeva APAC Commercial Summits in Singapore and Australia! Hear directly from Dirk Otto, General Manager Australia/ New Zealand at Boehringer Ingelheim on why you should attend. Register for Singapore Summit here: https://lnkd.in/gK4tj2C6 and Australia Summit here: https://lnkd.in/g6sGh4rB #APACSummits *Registration for the Veeva Summit is complimentary for all biopharma professionals.
Veeva Systems APAC’s Post
More Relevant Posts
-
From the hurdles that new FDA regulations present to the medtech sector to the continued funding challenges for biopharma companies, RSM's 2024 life sciences industry outlook explores what's ahead for middle market business leaders. https://rsm.buzz/3LvPIos
-
-
Swizzard's "why" is to bring medical innovation to Switzerland, and our goal is to guide our clients on how to navigate the Swiss healthcare landscape with success. As such, I am happy to kick-off our new post series "a comprehensive guide for biotech and pharmaceutical companies to enter the Swiss Market". Click on the second overview slide to learn what's coming soon.
The Swiss healthcare system is one of the best in the world. This quality is maintained with regulations, which in turn add to the increasing complexity of the system. In addition, Switzerland's federal structure leads to greater diversity in the healthcare system at a national level. Finally, Switzerland operates independently at the heart of Europe with its own drug approval authority and processes as well as specialized institutions. Translating the many strengths of the Swiss healthcare system into economically and socially beneficial measures demands sound knowledge of Switzerland and its healthcare system. Our new series "Navigating the Swiss healthcare landscape: A comprehensive guide for biotech and pharmaceutical companies" breaks down the challenges mentioned to enable a deeper and clearer understanding of the structure of the Swiss healthcare system. Follow us on LinkedIn or visit our blog to learn more and stay up to date: https://lnkd.in/gd_AGvu9 #SwizzardPharma #SwissHealthcareMarket #MarketAccess #MarketEntry Michael Zürcher, PhD EMBA | Bettina Schelbert | Karin Senn | Luc Heller | Arne Holicki | Yves Heller | Joël Heller | Julia Mühlethaler | Mathieu Bitz
-
The Swiss healthcare system is one of the best in the world. This quality is maintained with regulations, which in turn add to the increasing complexity of the system. In addition, Switzerland's federal structure leads to greater diversity in the healthcare system at a national level. Finally, Switzerland operates independently at the heart of Europe with its own drug approval authority and processes as well as specialized institutions. Translating the many strengths of the Swiss healthcare system into economically and socially beneficial measures demands sound knowledge of Switzerland and its healthcare system. Our new series "Navigating the Swiss healthcare landscape: A comprehensive guide for biotech and pharmaceutical companies" breaks down the challenges mentioned to enable a deeper and clearer understanding of the structure of the Swiss healthcare system. Follow us on LinkedIn or visit our blog to learn more and stay up to date: https://lnkd.in/gd_AGvu9 #SwizzardPharma #SwissHealthcareMarket #MarketAccess #MarketEntry Michael Zürcher, PhD EMBA | Bettina Schelbert | Karin Senn | Luc Heller | Arne Holicki | Yves Heller | Joël Heller | Julia Mühlethaler | Mathieu Bitz
-
From the hurdles that new FDA regulations present to the medtech sector to the continued funding challenges for biopharma companies, RSM's 2024 life sciences industry outlook explores what's ahead for middle market business leaders. https://rsm.buzz/3xSu4Yx
-
-
Paving the way for successful market access🏆 Interesting panel discussion with: Fredrik Olsson, CEO of Genovis Jessica Lundström, Director Market Access, Bristol Myers Squibb John Strobel, Managing Partner, LamaMed Access LLC Jonas Fredriksson, founder of XLNCE PHARMA Successfully entering foreign pharmaceutical markets requires thorough understanding of regulatory compliance, market demand, and competitive landscape. Companies must protect intellectual property, establish efficient supply chains, and form strategic local partnerships. Adapting to cultural diversity, adhering to ethical standards, and managing financial and political risks are crucial. Continuous monitoring and adaptation ensure long-term success. #GlobalForum2024
-
-
From the hurdles that new FDA regulations present to the medtech sector to the continued funding challenges for biopharma companies, RSM's 2024 life sciences industry outlook explores what's ahead for middle market business leaders. https://rsm.buzz/46wgWVX
-
-
In the ever-evolving world of pharmaceuticals, Europe is a dynamic landscape with immense potential. The recent changes in regulations bring opportunities and challenges. To maximize success, think beyond the traditional boundaries and explore the holistic European lens. https://ow.ly/YvzA50Q1vzy #EuropeanPharma #InnovateInEurope #PharmaStrategies
-
From the hurdles that new FDA regulations present to the medtech sector to the continued funding challenges for biopharma companies, RSM's 2024 life sciences industry outlook explores what's ahead for middle market business leaders. https://rsm.buzz/3SaKyC7
-
-
From the hurdles that new FDA regulations present to the medtech sector to the continued funding challenges for biopharma companies, RSM's 2024 life sciences industry outlook explores what's ahead for middle market business leaders. https://rsm.buzz/4cI0eou
-
